Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections (Q34975777)

5 August 2017

title

Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections (English)

1 reference

5 August 2017

0 references

2

Jean-Robert Ioset

1 reference

5 August 2017

Rob Don

1

1 reference

5 August 2017

publication date

28 August 2013

1 reference

5 August 2017

1 reference

5 August 2017

volume

141

1 reference

5 August 2017

issue

1

1 reference

5 August 2017

page(s)

140-146

1 reference

Target validation: linking target and chemical properties to desired product profile

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

Target assessment for antiparasitic drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

Target-based drug discovery: is something wrong?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

Drug discovery and development for neglected parasitic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

The amastigote forms of Leishmania are experts at exploiting host cell processes to establish infection and persist

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

Topoisomerases of kinetoplastid parasites as potential chemotherapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

Drug targets in Leishmania

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

Drugs for bad bugs: confronting the challenges of antibacterial discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

Development of an Alamar Blue viability assay in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

7 January 2021

Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

7 January 2021

Predictive modeling of anti-malarial molecules inhibiting apicoplast formation

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

7 January 2021

Thousands of chemical starting points for antimalarial lead identification

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

7 January 2021

Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

7 January 2021

Computational models for in-vitro anti-tubercular activity of molecules based on high-throughput chemical biology screening datasets

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

7 January 2021

Plate-based diversity subset screening: an efficient paradigm for high throughput screening of a large screening file

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

7 January 2021

Anti-infectives: can cellular screening deliver?

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

7 January 2021

Quantitative proteome profiling informs on phenotypic traits that adapt Leishmania donovani for axenic and intracellular proliferation

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

7 January 2021

N-myristoyltransferase inhibitors as new leads to treat sleeping sickness

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

7 January 2021

An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

7 January 2021

The kinetoplastid chemotherapy revisited: current drugs, recent advances and future perspectives.

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

7 January 2021

Development of protease inhibitors for protozoan infections

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

7 January 2021

Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges

1 reference

https://api.crossref.org/works/10.1017%2FS003118201300142X

7 January 2021

10.1017/S003118201300142X

Identifiers

DOI

1 reference

5 August 2017

1 reference